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Abstract
Background: There are contradictory reports about the relationship between fetuin-A and 
atherosclerotic process. Coronary artery disease is the most important cause of mortality in 
patients with chronic obstructive pulmonary disease (COPD). We aimed to investigate the 
association of serum fetuin-A level with mean carotid intima–media thickness (cIMT) and 
ankle-brachial index (ABI) in COPD.
Methods: We evaluated the association of serum fetuin-A level, mean cIMT and ABI in nor-
motensive subjects with COPD (n = 65) and with non-COPD (n = 50).
Results: Fetuin-A level was significantly lower (63.5 ± 19.8 ng/mL, 72.9 ± 16.2 ng/mL, 
p = 0.035) and C-reactive protein level higher (4 [1–10] vs. 3 [1–12] mg/dL, p = 0.034) in 
COPD patients than the control group. Compared to controls, fetuin-A level was significantly 
lower (63.5 ± 19.8 ng/mL, 72.9 ± 16.2 ng/mL, p = 0.035) and mean cIMT higher (0.69 
[0.50–0.98] vs. 0.62 [0.44–0.98] mm, p = 0.034, respectively) in the COPD group. There 
was a significant negative correlation between mean cIMT and fetuin-A levels (r = –0.320,  
p = 0.032). Age (b ± SE: 0.002 ± 0.001, p = 0.008) and fetuin-A (b ± SE: –0.002 ± 0.001, 
p = 0.035) were decisive for the mean cIMT.
Conclusions: There are increased cIMT values, decreased fetuin-A levels, but unchanged  
ABI values in patients with normotensive COPD. Age and fetuin-A were predictors for cIMT, 
while fetuin-A was negatively correlated with cIMT. (Cardiol J 2014; 21, 2: 191–197)
Key words: carotid intima–media thickness, chronic obstructive pulmonary 
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Introduction
Chronic obstructive pulmonary disease (COPD) 
is an important cause of morbidity and mortality all 
over the world, and occurs as a result of an abnor-
mal, irreversible and progressive inflammatory re-
sponse of airways to smoking and noxious particles 
or gases [1]. Atherosclerosis and coronary artery 
disease (CAD) are some of the co-morbidities of 
COPD, which is considered part of a chronic sy-
stemic inflammatory syndrome. COPD is a strong 
risk factor for cardiovascular (CV) events and dou-
bles the risk of CV morbidity and mortality [2, 3]. 
There is a relationship between atherosclerosis 
192 www.cardiologyjournal.org
Cardiology Journal 2014, Vol. 21, No. 2
and inflammation which plays an important role in 
all stages of atherosclerosis. Many studies have 
shown that similar inflammatory markers, such 
as tumor necrosis factor (TNF) and interleukin 6 
(IL-6), increase in COPD and atherosclerosis [4–8].
Fetuin-A is a blood protein whose molecular 
weight is 60 kDa and which is secreted from the 
liver. A potent inhibitor of systemic calcification, 
fetuin-A has a role in metabolic pathways such as 
calcium homeostasis, insulin sensitivity, promoting 
phagocytosis of apoptotic cells and bone deve-
lopment [9–11]. The association of lower fetuin-A, 
which is a novel biomarker, with COPD [12], late 
macrovascular complications in diabetic patients 
and subclinical atherosclerosis has been recently 
investigated [13–15]. The carotid intima–media 
thickness (cIMT) measurement, which is a non-
-invasive tool to track changes in arterial walls, 
is used to detect the presence of early subclinical 
atherosclerosis [16]. We sought to determine 
whether there was any relationship between cIMT 
and fetuin-A levels in patients with COPD; such 
a relationship has not been well documented in 
the literature.
Methods
Subjects
This study was carried out in our cardiology 
and chest outpatient clinics between September 
2010 and October 2012. One hundred and thirty 
subjects were initially selected for the study 
and they were divided into two groups of COPD 
and control. The study group was composed of 
80 patients with COPD, between 35 and 65 years 
of age. Eight people with CAD and 7 people with 
heart failure were excluded from the study. As 
a result, 65 patients made up the sample. There 
were 36 subjects with dyslipidemia and 41 sub-
jects were smokers in the patient group. There 
were no hypertensive and diabetic subjects in 
the COPD group. The control group consisted 
of 50 non-COPD subjects with age, sex and CV 
risk factors matched to the COPD group. There 
were 26 subjects with dyslipidemia in the control 
group. The control group did not include diabetic 
or hypertensive individuals or smokers. Subjects 
with dyslipidemia in both groups were taking statin 
medication. Patients with heart failure, diabetes 
mellitus, chronic liver disease, kidney failure, 
heart valve disease, peripheral artery disease, and 
CAD were excluded from the study. For the study, 
ethical approval was obtained from the local ethics 
committee and written informed consent was 
obtained from each patient in order to participate 
in the study.
Study protocols
Baseline characteristics such as age, gender, 
height, weight, body mass index, smoking, hyper-
tension, diabetes and hyperlipidemia were recor-
ded for the study and control groups. Patients were 
asked to fast overnight at least 12 h; afterwards, 
antecubital venous blood samples were collected 
for the measurement of fasting glucose, total chole-
sterol (TC), triglyceride (TG), high density lipopro-
tein cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), C-reactive protein (CRP) and 
fetuin-A. For fetuin-A measurements blood was 
collected in separate tubes and centrifuged, plasma 
was separated and stored at –80°C.
Biochemical analyses
Following an overnight fast, blood samples 
were collected for biochemical analysis at same 
time intervals (8:00 to 11:00). A standard en-
zymatic method using an auto-analyzer (AU680 
auto-analyzer [Beckman Coulter, Brea, CA]) was 
used for the measurement of fasting glucose, TC, 
HDL-C, LDL-C and TG levels. A standard nephe-
lometry method was used for the measurement of 
CRP levels (Cobas 311, Roche Diagnostics, Mann-
heim, Germany) with a sensitivity of 0.1 mg/L. 
Blood samples taken for fetuin-A were centrifuged 
and the separated serum samples stored at –80oC 
until they were analyzed.
Fetuin-A assay
Serum concentrations of fetuin-A were mea-
sured by using a human fetuin-A ELISA kit (Bio-
Vendor Laboratory Medicine, Inc., Brno, Czech 
Republic) in an ELISA plate reader (ELX 800 Multi-
-Plate Reader, Bio-tek Instruments, Inc., Winooski, 
VT, USA). Performance data were provided by the 
manufacturer. The minimum detectable concen-
tration for fetuin-A was 5 ng/mL. The measured 
intra-assay and inter-assay variability coefficients 
were 3.9% and 2.6%, respectively. Reference range 
in healthy subjects has not been defined by the 
manufacturer yet. A study reveals its normal range 
as 15–90 ng/mL, however, there is poor agreement 
between plasma fetuin-A measurements made 
using different ELISA methods [17].
Pulmonary function tests
Pulmonary function tests included forced 
expiratory volume in 1 s (FEV1) and forced vital 
capacity (FVC); FEV1/FVC were measured with 
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Jaeger MasterScope spirometer (VIASYS He-
althcare, Germany). Tests were repeated at least 
3 times in the sitting position and the best test was 
accepted as the final result to evaluate the per-
centage of values predicted by the spirometer’s 
software program. COPD was diagnosed according 
to the criteria of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD). The protocol 
for lung function measurements conformed to the 
American Thoracic Society recommendations [18]. 
According to their pulmonary function test, 17 pa-
tients were assigned stage I, 38 patients — stage II, 
6 patients — stage III and 4 patients — stage IV. 
After examination in the chest outpatient clinic, 
patients were invited to cardiology outpatient clinic 
for the measurement of cIMT and ankle-brachial 
index (ABI).
Ultrasonographic measurement  
of the cIMT and ABI parameters
Ultrasonographic and echocardiographic me-
asurements were performed by a cardiologist 
who was unaware of the case-control status of the 
subjects. Three different measurements for cIMT 
were performed, and the average was taken.
Carotid intima–media thickness  
measurements
All participants were at rest for 10 min before 
the examination, and placed in the supine position 
with their head tilted backwards. The right and 
left common carotid arteries were measured with 
real time scanner and with a synchronized ECG 
(Esaote MyLab 50, Genoa, Italy) after visualization 
using a 7.5 MHz linear array transducer using the 
semi-automated-guided technique radiofrequency-
-Quality Intima Media Thickness (QIMT; Esaote, 
Maastricht, Holland). A 1-cm segment was focused 
in the region of the first 2 cm below the common 
carotid artery bulb, and posterior wall IMT was 
measured. cIMT was defined as the average of the 
right and left cIMT.
Ankle brachial pressure index  
measurements
After the patients were at rest for 5–10 min in 
the supine position with the patient’s arms and legs 
at the same level as the heart, a pneumatic cuff was 
placed above the antecubital fossa, and an 8 mHz 
continuous wave hand-held Doppler probe (Sono-
trax – 8 MHz Sonotrax Ultrasonic Vascular Pocket 
Doppler, stork RADIO LLC, Boca Raton, FL, 
USA) was placed on the brachial artery. After the 
pneumatic cuff was inflated to at least 20 mm Hg 
above suprasystolic pressure, cuff pressure was 
gradually reduced. The first sound heard was 
recorded as brachial systolic blood pressure (BP). 
This was repeated for the other arm and the 
highest one was used for the calculation of ABI. To 
measure ankle systolic BP, the BP cuff was placed 
5 cm above the medial malleolus on the each ankle. 
Then, both lower extremities’ systolic BP were 
measured in the same way for the dorsalis pedis 
and tibialis posterior artery. The ABI is calculated 
by dividing the higher systolic BP at the ankle 
by the higher systolic BPs in the arm. From the 
calculated results, the lowest value was defined as 
the ABI. An ABI value less than 0.9 was considered 
to represent peripheral vascular disease [19, 20].
The cIMT and ABI measurements of 20 pa-
tients with COPD were re-examined after 10 days 
to determine the coefficients of variation between 
visits. These were 3.5% and 3.1% for cIMT and 
ABI, respectively.
Statistical analysis
Data were analyzed using the Predictive 
Analysis Software (PASW) Statistics 18 (SPSS 
Inc., Chicago, IL, USA). A Kolmogorov-Smirnov 
test was used to check continuous variable dis-
tributions. Descriptive statistics were expressed 
as mean ± standard deviation for the paramet-
ric data, or median (interquartile range) for the 
non-parametric data. For the comparison of the 
two groups, the independent t-test was used 
for normally distributed variables, whereas the 
Mann-Whitney U test was used for non-normally 
distributed variables, while the c2 test was used for 
categorical variables. Spearman rank correlation 
analysis was employed to estimate the relationship 
between test parameters. A p value < 0.05 was 
considered statistically significant. After entering 
univariate predictors with p < 0.2, multivariate li-
near regression analysis was performed to detect the 
independent variables affecting cIMT parameters.
Results
Anthropometric, clinical features  
and biochemical variables
A total of 65 patients with COPD (39 male, 
60%), and 50 non-COPD control subjects (29 male, 
58%) were evaluated. The mean duration of 
the disease and the mean duration of smoking of 
the study group was 11 ± 4.2 and 28 ± 4.7 years, 
respectively. The mean age, male percentage and 
body mass index of the COPD group and the control 
group were similar (61.7 ± 10.6 vs. 60.2 ± 12.9 years, 
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p = 0.248; n = 39 [60%] vs. n = 29 [58%], 
p = 0.141) and (26 ± 3.5 vs. 25.8 ± 2.6 kg/m2, 
p = 0.865), respectively. Dyslipidemia rates did 
not differ between the study and control groups 
(n = 36 [55.3%], n = 26 [52%], p = 0.564). Addi-
tionally, there was no difference between the two 
groups in terms of systolic BP, TC, TG, HDL-C, 
LDL-C, fasting glucose, uric acid (all values of 
p > 0.05). The COPD group had higher CRP levels 
(4 [1–10] vs. 3 [1–12] mg/L, p = 0.034) and lower 
fetuin-A levels (63.5 ± 19.8 vs. 72.9 ± 16.2 ng/mL, 
p = 0.035) compared to the control group (Table 1).
Spirometer values
The COPD group had a lower FEV1 (%) 
(61.1 ± 17.6 vs. 100.2 ± 12.1, p < 0.001), FVC 
(84.8 ± 18.6 vs. 96.4 ± 9.5%, p = 0.002), FEV1/ 
/FVC (55.7 [35–81] vs. 86.4 [68–95], p < 0.001) 
compared to the control group (Table 1).
Carotid IMT and ABI
Compared with the control group, the COPD 
group had higher cIMT (0.69 [0.50–0.98] vs. 0.62 
[0.44–0.98] mm, p = 0.034, respectively). ABI 
values were not statistically different between 
the two groups (1.08 [1–1.31] vs. 1.11 [1.0–1.47], 
p = 0.278; Table 2). There was a negative correla-
tion between fetuin-A and cIMT values in the COPD 
group, but not in the control group (r = –0.320, 
p = 0.032 and r = –0.116, p = 0.423) (Figs. 1, 2). 
No correlation was seen between fetuin-A and ABI 
values (r = –0.06, p = 0.691).
In univariate regression analysis, age, FEV1, 
systolic BP, LDL-C, fasting glucose, CRP and 
fetuin-A levels were found as parameters with 
p < 0.2. After these variables, in multivariate 
regression analysis, the predictors of increased 
cIMT were age (b ± SE: 0.002 ± 0.001, p = 0.008) 
and fetuin-A levels (b ± SE: –0.002 ± 0.001, 
p = 0.035) (Table 3).
Discussion
No study so far has investigated the relation-
ship between fetuin-A, cIMT and ABI in patients 
with COPD. We particularly studied subjects 
with no manifest atherosclerosis to determine 
the association between COPD and subclinical 
atherosclerosis concerning serum fetuin-A levels. 
The present study revealed the following findings: 
Table 1. Anthropometric, clinical features, and biochemical parameters of the chronic obstructive pul-
monary disease (COPD) and control groups.
COPD group (n = 65) Controls group (n = 50) P*
Age [years] 61.7 ± 10.6 60.2 ± 12.9 0.248
Gender, male 39 (60%) 29 (58%) 0.141
Body mass index [kg/m2] 26 ± 3.5 25.8 ± 2.6 0.865
Current smoker 41 (63%) 0 (0%) < 0.001
Duration of smoking [years] 28 ± 4.7 0 (0%) < 0.001
Duration of disease [years] 11 ± 4.2 0 (0%) < 0.001
Dyslipidemia 36 (55.3%) 26 (52%) 0.564
FEV1 [%] 61.1 ± 17.6 100.2 ± 12.1 < 0.001
FVC [%] 84.8 ± 18.6 96.4 ± 9.5 0.002
FEV1/FVC 55.7 (35–81) 86.4 (68–95) < 0.001
Systolic blood pressure [mm Hg] 126 ± 7 128 ± 6 0.563
Diastolic blood pressure [mm Hg] 81 ± 2.7 79 ± 2.9 0.441
Total cholesterol [mg/dL] 200 (115–318) 191 (121–260) 0.726
Triglycerides [mg/dL] 124 (43–368) 161 (52–388) 0.394
HDL-C [mg/dL] 44 (18–69) 42 (30–181) 0.806
LDL-C [mg/dL] 137 ± 39 130 ± 37 0.472
Uric acid [mg/dL] 6.5 ± 3.3 6.6 ± 3.8 0.968
Fasting glucose [mg/dL] 87 (53–113) 73 (57–113) 0.314
C-reactive protein [mg/dL] 4 (1–10) 3 (1–12) 0.034
Fetuin-A [ng/mL] 63.5 ± 19.8 72.9 ± 16.2 0.035 
Data are presented as mean ± SD and median (interquartile range); *c2 test, Mann-Whitney U test and Student’s t test; FEV1 — forced expira-
tory volume in 1 s; FVC — forced vital capacity; HDL — high density lipoprotein cholesterol; LDL — low density lipoprotein cholesterol
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first, patients with normotensive COPD had sig-
nificantly higher cIMT values, higher CRP levels, 
and lower fetuin-A levels than the control group. 
Second, there was a negative correlation between 
cIMT and fetuin-A, and the predictors of increased 
cIMT were age and fetuin-A levels. Third, ABI 
values did not differ significantly in patients with 
COPD compared to the control group and there 
was also no relationship between ABI values and 
fetuin-A levels.
Increased cIMT was shown to be a strong 
indicator of future CV events [16]. There are 
many studies on the relationship between incre-
Figure 1. A negative linear correlation between serum 
fetuin-A levels and increasing mean common carotid 
artery intima–media thickness (CCA-IMT) is shown on 
scatter diagram in the chronic obstructive pulmonary 
disease group (Spearman rank correlation coefficient 
r = –0.320, p = 0.032).
Table 2. The parameters of carotid intima–media thickness and ankle-brachial index values of the chro-
nic obstructive pulmonary disease (COPD) and control groups.
COPD group (n = 65) Control group (n = 50) P*
CCA-IMT [mm] 0.69 (0.50–0.98) 0.62 (0.44–0.98) 0.034
Ankle-brachial index 1.08 (1–1.31) 1.11 (1.0–1.47) 0.278
Left ventricular ejection fraction [%] 66 (50–69) 68 (58–74) 0.856
*Mann-Whitney U test; CCA-IMT — common carotid artery intima–media thickness
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Figure 2. No correlation was shown between mean 
common carotid artery intima–media thickness (CCA-
-IMT) and serum fetuin-A levels in the control group 
(Spearman rank correlation coefficient r = –0.116; 
p = 0.423).
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Table 3. Univariate and multivariate analysis for 
predictors of carotid intima–media thickness.
Unstandardized  
b ± SE
P
Univariate analysis
Age [years]* 0.002 ± 0.001 0.039
Body mass index [kg/m2] –0.02 ± 0.003 0.453
FEV1 [%]* 0.001 ± 0.001 0.150
FVC [%] 0.001 ± 0.001 0.385
FEV1/FVC 0.001 ± 0.001 0.256
Systolic BP [mm Hg]* 0.001 ± 0.001 0.197
Diastolic BP [mm Hg] 0.001 ± 0.001 0.432
Total cholesterol [mg/dL] 0.001 ± 0.001 0.704
Triglycerides [mg/dL] 0.001 ± 0.001 0.923
HDL-C [mg/dL] 0.001 ± 0.001 0.878
LDL-C [mg/dL]* 0.001 ± 0.002 0.184
Uric acid [mg/dL] 0.001 ± 0.002 0.587
Fasting glucose [mg/dL]* 0.001 ± 0.001 0.182
C-reactive protein [mg/dL]* –0.002 ± 0.001 0.129
Fetuin-A [ng/mL]* –0.001 ± 0.001 0.032
Multivariate analysis
Age [years] 0.002 ± 0.001 0.008
Fetuin-A [ng/mL] –0.002 ± 0.001 0.035 
Unstandardized b ± SE values indicate the change in IMT [mm] per 
1 — SD change in variables; *Variables included in multivariate 
models when univariate analysis showed parameters with p < 0.2; 
BP — blood pressure; FEV1 — forced expiratory volume in 1 s;  
FVC — forced vital capacity; HDL — high density lipoprotein cho-
lesterol; LDL — low density lipoprotein cholesterol
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ased cIMT and COPD; age and FEV1 have also 
been found to be predictors for increased cIMT 
in patients with COPD [21–23], as well as other 
atherosclerotic risk factors such as hypertension, 
diabetes and dyslipidemia. We did not observe 
any correlation between cIMT and FEV1. Similar 
to our results, some previous studies have shown 
increased cIMT and decreased ABI, an indicator 
for generalized atherosclerosis, in patients with 
COPD and in subjects with reduced FEV1 [21–24]. 
Although it is known that hypertension is one of 
the most important risk factors for atherosclerosis, 
cIMT is strongly related not only to systolic BP, 
but also age and dyslipidemia [25]. In our study, all 
participants with dyslipidemia were subjected to 
regular treatment. We assume that the contributing 
effects of dyslipidemia to cIMT might be running 
slow in the study participants.
Because ABI associates with CAD, and defect 
stenosis > 50% in major leg arteries [26], we par-
ticularly investigated ABI values of all the study 
subjects to exclude peripheral artery disease. 
Given that there were no abnormal ABI values in 
our COPD patients, we assume that this might be 
related to the condition of their mild and moderate 
stage of COPD and to non-hypertensive as well as 
anti-hyperlipidemic treatment. While decreased 
ABI values are associated with prominent athero-
sclerosis [27], increased cIMT values are related 
potentially to early atherosclerosis [16].
There has been a number of contradictory 
reports about the relationship between fetuin-A 
and atherosclerotic process. While most studies 
showed that fetuin-A was a negative acute-phase 
reactant and had anti-inflammatory effects [11, 
12], some studies claimed that higher fetuin-A 
levels were associated with ischemic heart disease 
and insulin resistance [28, 29]. Therefore, more 
investigation is warranted to determine the role 
of fetuin-A in the pathophysiology of CV disease. 
Eraso et al. [13] showed that lower fetuin-A was 
associated with peripheral arterial disease in type 2 
diabetes. It is known that, in fact, hypertriglyce-
ridemia — which might be often a metabolic part 
of diabetes mellitus — is associated with increased 
fetuin A levels [30].
Minas et al. [12] suggested that fetuin-A is 
decreased in COPD, especially during exacerba-
tions. In the study, the patients with COPD had 
lower fetuin-A levels than the control group. Our 
results support the idea that the fetuin-A is a ne-
gative inflammatory marker for both COPD and 
atherosclerosis, even though no correlation was 
found between fetuin-A and FEV1 in our study. 
According to our study, fetuin-A level, as well as 
age, was surprisingly a predictor of increased cIMT. 
Therefore, in fetuin-A deficiency, the increase in 
inflammatory conditions and the increase in va-
scular calcification may play a role as an important 
contributor to the increased cIMT.
Limitations of the study
There are several limitations of this study. 
Firstly, the most important limitation is that we 
studied a relatively small number of patients with 
stage 3 and 4 COPD. Secondly, all the patients in 
the COPD group were receiving regular treat-
ment with inhaled bronchodilators and steroids, 
and some subjects in both groups were on anti-
-hyperlipemic agents, which may be a factor in 
mitigating the impact of fetuin-A on cIMT and ABI, 
which are markers of atherosclerosis. We did not 
investigate whether these agents have an effect on 
the study variables.
Conclusions
Lower fetuin-A levels are related with COPD, 
but not with any particular stage of COPD, and are 
also negatively correlated with cIMT. Additionally, 
an increased cIMT is associated with COPD and 
age in non-hypertensive subjects. Further studies 
are necessary to detect the contribution of the se-
rum inflammatory markers such as IL-6 and TNF, 
as well as fetuin-A, on the association between 
COPD and CV risk in a large number of patients 
with mild, moderate and severe COPD.
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